Safety and efficacy of remimazolam sedation and propofol sedation in patients undergoing colonoscopic polypectomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046928

Enrollment

Unknown

Registered

2021-05-31

Start date

2021-06-04

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonic polyps

Interventions

Propofol group:Propofol

Remimazolam group:Remimazolam

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years, ASA I-II level; 2. The operation time is 20min-1h; 3. BMI 18.5-23.9; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Emergency surgery; 2. Patients with high risk of full stomach, reflux and aspiration; 3. Those who are allergic to benzodiazepines and opioids; 4. Those who have taken sedative, analgesic or antidepressant drugs within 24 hours; 5. Pregnant and lactating women; 6. Abnormal liver and kidney function; 7. Past drug use history; 8. Participate in other clinical research recently; 9. Patients who cannot cooperate with communication.

Design outcomes

Primary

Measure	Time frame
Recovery time;Sedation success rate;	—

Secondary

Measure	Time frame
Blood pressrue;Heart rate;Blood oxygen saturation;Depth of anesthesia;	—

Countries

China

Contacts

Public ContactZhao Tonghang

Liaocheng People's Hospital

lcrmzxj@sina.com+86 15275662176

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026